Replies to post #9414 on Aurinia Pharmaceuticals Inc (AUPH)

[CoolG73]

Now for those asking what is the comparison between the CR of VCS and the CR of Obinutuzumab of Roche, and accounting for the NO RESCUE THERAPY requirement , we have the following :

Roche CR :

CR = 35% (including the Sediment criteria)
CR = 43% excluding the Sediment criteria(aligned with AURORA criterias)
CR = 38% Accounting for the no rescue requirement (aligned with the AURORA study protocol)

So to make a fair comparison, you should compare to a CR of 38% at 52 weeks, and this doesn't account for the fact that we are using half the amount of steroid

[biotech_researcher]

CoolG, since we are at the same price we were two years ago, does this Roche study indicate we can add to our AUPH position??